News MedBiome Inc.

MedBiome News and Technology Updates

MedBiome licenses the MetaLab metaproteomic software

Published on: 05 February, 2020

MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is…

MedBiome Licenses the RapidAIM technology from the University of Ottawa.

Published on: 30 January, 2020

MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a…

MedBiome Announces the Appointment of Shane Climie as Vice-President Business Development

Published on: 19 January, 2020

MedBiome, a company specializing in the development of therapeutics targeting the gut microbiome, today announced that Dr. Shane Climie has…

MedBiome will be at Bio Europe 2019

Published on: 12 October, 2019

Looking forward to multiple partnership meetings at Bio Europe 2019 in Hamburg.

96 well-plate RapidAIM assay

Published on: 16 September, 2019

MedBiome's founders reported in Nature Comms. on the development of 96-well plate approach that maintains functional and compositional…

MedBiome will be at Bio International from June 3rd to June 6th 2019

Published on: 01 June, 2019

Looking forward to multiple partnership meetings at Bio International in Philadelphia.

Medbiome's founders developed guidelines for metaproteomic for the study of human microbiomes

Published on: 18 May, 2019

Dr. Daniel Figeys, co-founder of MedBiome, published a new set of guidelines to perform and analyze metaproteomics studies of human…

MedBiome will be at MaRS HealthKick Invest in Toronto April 2-3 2019

Published on: 11 March, 2019

MedBiome is pleased to announce its participation in the MaRS HealthKick Invest 2019 event.

MedBiome will be at BIO 2019 in Philadelphia June 3-6 2019

Published on: 28 February, 2019

MedBiome is glad to announce its participation to **[BIO 2019](https://convention.bio.org/2019/). We will be available for meeting during…

Founders of MedBiome receive 2.9M$ to further develop the RapidAIM microbiome drug screening platform

Published on: 26 February, 2019

Dr. Daniel Figeys, Dr. Alain Stintzi and their teams at the University of Ottawa are further developing the RapidAIM platform. The team is…

MedBiome participates in Bio Europe

Published on: 05 November, 2018

Dr. Alain Stintzi and Dr. Daniel Figeys were at Bio Europe in Copenhagen in November 2018. They presented the RapidAIM platform to rapidly…

MedBiome's Founders publish in Nature Communications

Published on: 21 July, 2018

MedBiome's founders published an article on the associations between microbiome and intestinal extracellular vesicle proteins in pediatric…

News

MedBiome focuses on the development of drugs that target the human microbiome. MedBiome Inc. was launched in 2018 as the result of technologies developed at the University of Ottawa.